Fig 1: Effects of shikonin on the expression of CEBPD in IL-17-stimulated HaCaT cells. (A) Relative CEBPD and (B) K17 mRNA expression levels in HaCaT cells treated with IL-17 and/or shikonin. (C) Representative western blots for CEBPD and K17 protein levels in HaCaT cells treated with IL-17 and/or shikonin and quantitative analysis. ß-actin was used as the loading control. (D) Proliferation rates of CEBPD-siRNA transfected HaCaT cells treated with IL-17 and/or shikonin for 24, 48 or 72 h. Data are presented as the mean ± SEM of six replicates from three independent experiments. (E) CEBPD and (F) K17 mRNA expression levels in CEBPD-siRNA cells treated with IL-17 and/or shikonin. (G) Representative western blots for CEBPD and K17 proteins in CEBPD-siRNA cells treated with IL-17 and/or shikonin and quantitative analysis. ß-actin was used as the loading control. *P<0.05, vs. control. IL, interleukin; CEBPD, CCAAT/enhancer-binding protein d; K17, keratin 17; NC, cells transfected with a negative control scrambled shRNA.
Fig 2: Effects of shikonin on CEBPD expression in an IMQ-induced psoriatic mouse model. (A) Representative IHC images showing in situ expression of CEBPD in the mouse skin. Magnification, ×400. (B) Mean optical density of CEBPD. (C) CEBPD and K17 protein expression levels in psoriatic lesions. *P<0.05, vs. CON. CEBPD, CCAAT/enhancer-binding protein d; K17, keratin 17; IMQ, imiquimod, SO, shikonin oil; MO, medium oil; CON, control; IOD, integrated optical density.
Supplier Page from Abcam for Anti-CEBP Delta/CEBPD antibody